Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

For paragraph IV challenge research

— Pharmaceutical company, USA

To get accurate and reliable patency status in Saudi Arabia and Middle East countries

— Director, business development, Saudi Arabia

To identify possible time generic approval and launch

— Formulation research, South Korea

To find patent expiry information for Australia

— Pharmaceutical consulting, Australia

To gain knowledge of expiry of patents in anticipation of generic/biosimilars entering the market

— Clinical pharmacist, state drug formulary committee, USA

Generated: May 23, 2017

DrugPatentWatch Database Preview

DUAVEE Drug Profile

« Back to Dashboard

What is the patent landscape for Duavee, and when can generic versions of Duavee launch?

Duavee is a drug marketed by Wyeth Pharms Pfizer and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-two patent family members in forty countries.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

Summary for Tradename: DUAVEE

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Clinical Trials: see list4
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DUAVEE at DailyMed

Pharmacology for Tradename: DUAVEE

Ingredient-typeEstrogens, Conjugated (USP)
Drug ClassEstrogen
Estrogen Agonist/Antagonist
Mechanism of ActionEstrogen Receptor Agonists
Selective Estrogen Receptor Modulators
ADD ALERT
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes5,998,402► SubscribeYY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes8,815,934► SubscribeY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes7,138,392► SubscribeYY ► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► Subscribe
Wyeth Pharms Pfizer
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL022247-001Oct 3, 2013RXYesYes6,479,535► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Predict branded drug patent expiration
  • Uncover prior art in abandoned patent applications and expired patents
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

For a better understanding of small molecule opportunities and the litigation strategies employed by the brands in PIV cases

— Supply chain manager, USA

To get patent expiration dates and find out when generics plan to advertise and enter the market

— Pharmacist, USA

To obtain patent expiration information, so that the timeline for registration and launch of our generic products can be optimized.

— Business development manager, generics distribution company, Singapore

For information on when certain branded drugs expire, and where

— Director of procurement for clinical trials, USA

To get information on ANDA & Paragraph IV challenges

— Global head business team (API & generics), Netherlands

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot